WEKO3
アイテム
{"_buckets": {"deposit": "f110591a-2339-47de-bce0-bd2fa3f2be2f"}, "_deposit": {"created_by": 2, "id": "1787", "owners": [2], "pid": {"revision_id": 0, "type": "depid", "value": "1787"}, "status": "published"}, "_oai": {"id": "oai:nagasaki-u.repo.nii.ac.jp:00001787", "sets": ["9"]}, "author_link": ["8390", "8385", "8380", "8383", "8388", "8389", "8393", "8381", "8384", "8387", "8378", "8391", "8386", "8392", "8382", "8394", "8379"], "item_2_biblio_info_6": {"attribute_name": "書誌情報", "attribute_value_mlt": [{"bibliographicIssueDates": {"bibliographicIssueDate": "2019-06", "bibliographicIssueDateType": "Issued"}, "bibliographicPageEnd": "8", "bibliographicPageStart": "1", "bibliographicVolumeNumber": "132", "bibliographic_titles": [{"bibliographic_title": "Lung Cancer"}]}]}, "item_2_description_4": {"attribute_name": "抄録", "attribute_value_mlt": [{"subitem_description": "Objectives: To evaluate the efficacy and safety, we conducted a randomized phase II study of pemetrexed (Pem) versus Pem + bevacizumab (Bev) for elderly patients \nwith non-squamous non-small cell lung cancer (NSqNSCLC). Patients and methods: The eligibility criteria were as follows: NSqNSCLC, no prior therapy,stage IIIB/IV disease or postoperative recurrence, age: ?75 years, performance status (PS): 0?1, and adequate bone marrow function. The patients were randomly assigned (1:1 ratio)to receive Pem or Pem + Bev. The primary endpoint was progression-free survival (PFS).The secondary endpoints were the response rate, OS, toxicities, and cost-effectiveness. \nResults: Forty-one patients were enrolled and 40 (20 from each group) were assessable. \nTheir characteristics were as follows: male/female = 23/17; median age (range) = 78 (75?83); stage IIIB/IV/postoperative recurrence = 1/30/9; PS 0/1 = 11/29. All cases involved adenocarcinoma.There was no significant intergroup difference in PFS and the median PFS (95% confidence interval)\n values of the Pem and Pem + Bev groups were 5.4 (3.0?7.4) and 5.5 (3.6?9.9) months, respectively (p = 0.66). The response rate was significantly higher in the Pem + Bev group(15% vs. 55%, p = 0.0146), and there was no significant difference in OS (median: 16.0 vs. 16.4 months, p = 0.58). Grade 3 and 4 leukopenia, neutropenia,and thrombocytopenia were seen in 10 and 30, 20 and 55, and 5 and 5 cases, respectively.\n Drug costs were higher in the Pem + Bev group (median: 1,522,008 vs. 3,368,428 JPY, p = 0.01). No treatment-related deaths occurred. Conclusions: Adding Bev to Pem did not result in improved survival in the elderly NSqNSCLC patients. Compared with Pem + Bev, Pem monotherapy had similar effects on survival, a more favorable toxicity profile, and was more cost-effective in elderly NSqNSCLC patients. Pem monotherapy might be one of the optional regimen for NSqNSCLC patients aged ?75 years.", "subitem_description_type": "Abstract"}]}, "item_2_description_63": {"attribute_name": "引用", "attribute_value_mlt": [{"subitem_description": "Lung Cancer, 132, pp.1-8; 2019", "subitem_description_type": "Other"}]}, "item_2_publisher_33": {"attribute_name": "出版者", "attribute_value_mlt": [{"subitem_publisher": "Elsevier B.V."}]}, "item_2_relation_12": {"attribute_name": "DOI", "attribute_value_mlt": [{"subitem_relation_type": "isVersionOf", "subitem_relation_type_id": {"subitem_relation_type_id_text": "10.1016/j.lungcan.2019.01.008", "subitem_relation_type_select": "DOI"}}]}, "item_2_rights_13": {"attribute_name": "権利", "attribute_value_mlt": [{"subitem_rights": "c 2019 Elsevier B.V. This manuscript version is made available under the CC-BY-NC-ND 4.0 license http://creativecommons.org/licenses/by-nc-nd/4.0/"}]}, "item_2_source_id_7": {"attribute_name": "ISSN", "attribute_value_mlt": [{"subitem_source_identifier": "01695002", "subitem_source_identifier_type": "ISSN"}]}, "item_2_version_type_16": {"attribute_name": "著者版フラグ", "attribute_value_mlt": [{"subitem_version_resource": "http://purl.org/coar/version/c_ab4af688f83e57aa", "subitem_version_type": "AM"}]}, "item_creator": {"attribute_name": "著者", "attribute_type": "creator", "attribute_value_mlt": [{"creatorNames": [{"creatorName": "Fukuda, Minoru"}], "nameIdentifiers": [{"nameIdentifier": "8378", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Kitazaki, Takeshi"}], "nameIdentifiers": [{"nameIdentifier": "8379", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Ogawara, Daiki"}], "nameIdentifiers": [{"nameIdentifier": "8380", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Ichiki, Masao"}], "nameIdentifiers": [{"nameIdentifier": "8381", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Mukae, Hiroshi"}], "nameIdentifiers": [{"nameIdentifier": "8382", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Maruyama, Riichiroh"}], "nameIdentifiers": [{"nameIdentifier": "8383", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Nakagaki, Noriaki"}], "nameIdentifiers": [{"nameIdentifier": "8384", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Shimada, Midori"}], "nameIdentifiers": [{"nameIdentifier": "8385", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Ikeda, Takaya"}], "nameIdentifiers": [{"nameIdentifier": "8386", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Kishimoto, Junji"}], "nameIdentifiers": [{"nameIdentifier": "8387", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Harada, Taishi"}], "nameIdentifiers": [{"nameIdentifier": "8388", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Seto, Takashi"}], "nameIdentifiers": [{"nameIdentifier": "8389", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Ebi, Noriyuki"}], "nameIdentifiers": [{"nameIdentifier": "8390", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Takayama, Koichi"}], "nameIdentifiers": [{"nameIdentifier": "8391", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Okamoto, Isamu"}], "nameIdentifiers": [{"nameIdentifier": "8392", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Ichinose, Yukito"}], "nameIdentifiers": [{"nameIdentifier": "8393", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Sugio, Kenji"}], "nameIdentifiers": [{"nameIdentifier": "8394", "nameIdentifierScheme": "WEKO"}]}]}, "item_files": {"attribute_name": "ファイル情報", "attribute_type": "file", "attribute_value_mlt": [{"accessrole": "open_date", "date": [{"dateType": "Available", "dateValue": "2020-12-18"}], "displaytype": "detail", "download_preview_message": "", "file_order": 0, "filename": "LC132_1.pdf", "filesize": [{"value": "555.7 kB"}], "format": "application/pdf", "future_date_message": "", "is_thumbnail": false, "licensetype": "license_free", "mimetype": "application/pdf", "size": 555700.0, "url": {"label": "LC132_1.pdf", "url": "https://nagasaki-u.repo.nii.ac.jp/record/1787/files/LC132_1.pdf"}, "version_id": "a4e8e0be-e07a-4491-9ab5-b12ea6ae72e6"}]}, "item_keyword": {"attribute_name": "キーワード", "attribute_value_mlt": [{"subitem_subject": "pemetrexed", "subitem_subject_scheme": "Other"}, {"subitem_subject": "bevacizumab", "subitem_subject_scheme": "Other"}, {"subitem_subject": "lung cancer", "subitem_subject_scheme": "Other"}, {"subitem_subject": "elderly", "subitem_subject_scheme": "Other"}, {"subitem_subject": "NSqNSCLC", "subitem_subject_scheme": "Other"}]}, "item_language": {"attribute_name": "言語", "attribute_value_mlt": [{"subitem_language": "eng"}]}, "item_resource_type": {"attribute_name": "資源タイプ", "attribute_value_mlt": [{"resourcetype": "journal article", "resourceuri": "http://purl.org/coar/resource_type/c_6501"}]}, "item_title": "Randomized phase II study of pemetrexed or pemetrexed plus bevacizumab for elderly patients with previously untreated non-squamous non-small cell lung cancer: Results of the Lung Oncology Group in Kyushu (LOGIK1201)", "item_titles": {"attribute_name": "タイトル", "attribute_value_mlt": [{"subitem_title": "Randomized phase II study of pemetrexed or pemetrexed plus bevacizumab for elderly patients with previously untreated non-squamous non-small cell lung cancer: Results of the Lung Oncology Group in Kyushu (LOGIK1201)"}]}, "item_type_id": "2", "owner": "2", "path": ["9"], "permalink_uri": "http://hdl.handle.net/10069/39064", "pubdate": {"attribute_name": "公開日", "attribute_value": "2020-07-01"}, "publish_date": "2020-07-01", "publish_status": "0", "recid": "1787", "relation": {}, "relation_version_is_last": true, "title": ["Randomized phase II study of pemetrexed or pemetrexed plus bevacizumab for elderly patients with previously untreated non-squamous non-small cell lung cancer: Results of the Lung Oncology Group in Kyushu (LOGIK1201)"], "weko_shared_id": -1}
Randomized phase II study of pemetrexed or pemetrexed plus bevacizumab for elderly patients with previously untreated non-squamous non-small cell lung cancer: Results of the Lung Oncology Group in Kyushu (LOGIK1201)
http://hdl.handle.net/10069/39064
http://hdl.handle.net/10069/39064e12cb0d0-3174-4110-9f4a-7e8f4440d45a
名前 / ファイル | ライセンス | アクション |
---|---|---|
LC132_1.pdf (555.7 kB)
|
|
Item type | 学術雑誌論文 / Journal Article(1) | |||||
---|---|---|---|---|---|---|
公開日 | 2020-07-01 | |||||
タイトル | ||||||
タイトル | Randomized phase II study of pemetrexed or pemetrexed plus bevacizumab for elderly patients with previously untreated non-squamous non-small cell lung cancer: Results of the Lung Oncology Group in Kyushu (LOGIK1201) | |||||
言語 | ||||||
言語 | eng | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | pemetrexed | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | bevacizumab | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | lung cancer | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | elderly | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | NSqNSCLC | |||||
資源タイプ | ||||||
資源タイプ識別子 | http://purl.org/coar/resource_type/c_6501 | |||||
資源タイプ | journal article | |||||
著者 |
Fukuda, Minoru
× Fukuda, Minoru× Kitazaki, Takeshi× Ogawara, Daiki× Ichiki, Masao× Mukae, Hiroshi× Maruyama, Riichiroh× Nakagaki, Noriaki× Shimada, Midori× Ikeda, Takaya× Kishimoto, Junji× Harada, Taishi× Seto, Takashi× Ebi, Noriyuki× Takayama, Koichi× Okamoto, Isamu× Ichinose, Yukito× Sugio, Kenji |
|||||
抄録 | ||||||
内容記述タイプ | Abstract | |||||
内容記述 | Objectives: To evaluate the efficacy and safety, we conducted a randomized phase II study of pemetrexed (Pem) versus Pem + bevacizumab (Bev) for elderly patients with non-squamous non-small cell lung cancer (NSqNSCLC). Patients and methods: The eligibility criteria were as follows: NSqNSCLC, no prior therapy,stage IIIB/IV disease or postoperative recurrence, age: ?75 years, performance status (PS): 0?1, and adequate bone marrow function. The patients were randomly assigned (1:1 ratio)to receive Pem or Pem + Bev. The primary endpoint was progression-free survival (PFS).The secondary endpoints were the response rate, OS, toxicities, and cost-effectiveness. Results: Forty-one patients were enrolled and 40 (20 from each group) were assessable. Their characteristics were as follows: male/female = 23/17; median age (range) = 78 (75?83); stage IIIB/IV/postoperative recurrence = 1/30/9; PS 0/1 = 11/29. All cases involved adenocarcinoma.There was no significant intergroup difference in PFS and the median PFS (95% confidence interval) values of the Pem and Pem + Bev groups were 5.4 (3.0?7.4) and 5.5 (3.6?9.9) months, respectively (p = 0.66). The response rate was significantly higher in the Pem + Bev group(15% vs. 55%, p = 0.0146), and there was no significant difference in OS (median: 16.0 vs. 16.4 months, p = 0.58). Grade 3 and 4 leukopenia, neutropenia,and thrombocytopenia were seen in 10 and 30, 20 and 55, and 5 and 5 cases, respectively. Drug costs were higher in the Pem + Bev group (median: 1,522,008 vs. 3,368,428 JPY, p = 0.01). No treatment-related deaths occurred. Conclusions: Adding Bev to Pem did not result in improved survival in the elderly NSqNSCLC patients. Compared with Pem + Bev, Pem monotherapy had similar effects on survival, a more favorable toxicity profile, and was more cost-effective in elderly NSqNSCLC patients. Pem monotherapy might be one of the optional regimen for NSqNSCLC patients aged ?75 years. |
|||||
書誌情報 |
Lung Cancer 巻 132, p. 1-8, 発行日 2019-06 |
|||||
出版者 | ||||||
出版者 | Elsevier B.V. | |||||
ISSN | ||||||
収録物識別子タイプ | ISSN | |||||
収録物識別子 | 01695002 | |||||
DOI | ||||||
関連タイプ | isVersionOf | |||||
識別子タイプ | DOI | |||||
関連識別子 | 10.1016/j.lungcan.2019.01.008 | |||||
権利 | ||||||
権利情報 | c 2019 Elsevier B.V. This manuscript version is made available under the CC-BY-NC-ND 4.0 license http://creativecommons.org/licenses/by-nc-nd/4.0/ | |||||
著者版フラグ | ||||||
出版タイプ | AM | |||||
出版タイプResource | http://purl.org/coar/version/c_ab4af688f83e57aa | |||||
引用 | ||||||
内容記述タイプ | Other | |||||
内容記述 | Lung Cancer, 132, pp.1-8; 2019 |